ManRos Therapeutics is a development-stage pharmaceutical company engaged in the discovery and development of small molecule drugs against severe pathologies, namely solid tumors, leukemia, neurodegenerative disorders (Alzheimer’s and Parkinson’s diseases), or some renal diseases (including Polycystic Kidney Disease).
ManRos Therapeutics was founded by Dr. Laurent Meijer and Pr. Hervé Galons. Over the past decades, Dr. Laurent Meijer has gathered a deep knowledge of the cell division cycle mechanisms. This fundamental research led him to the identification and extensive characterization of several classes of regulators, mostly protein kinases.
Together with various chemists throughout the world, he identified and characterized several pharmacological families of protein kinases inhibitors, including olomoucine, R-roscovitine, purvalanol, indirubins, paullones, hymenialdisine, meriolins, etc... Among these, R-roscovitine (or seliciclib) is currently undergoing phase II clinical trials against lung and nasopharyngeal cancers in the USA.
Protein kinases indeed constitute one of the most promising screening targets for the discovery of new targeted therapies. For instance, Gleevec®, also known as imanitib tosylate, proved to be a spectacular success, and kinase inhibitors now make up a significant fraction of most major pharmaceutical companies’ pipelines.
Together with Hervé Galons, and other collaborators, ManRos Therapeutics has identified, characterized and patented several promising families of kinase inhibitors, some of which are derived from molecules of marine origin. We have demonstrated proof of concept data on various molecular, cellular and animal models, and we are carrying out pre-clinical studies. Building on our strong knowledge in kinase inhibitors, medicinal chemistry and organic synthesis, we aim to bring these molecules to clinical applications in various therapeutic indications.